Iron is one of the most fundamental nutrients in human physiology—essential for oxygen transport, energy production, immune function, and cognitive performance. When iron stores are depleted and oral supplementation is insufficient, poorly tolerated, or too slow to meet clinical need, intravenous iron sucrose (Venofer®) provides a direct, physician-supervised route to replenish iron levels. At The Longevity Center FL, Venofer IV infusions are administered under the direction of Dr. Benjamin Kosubevsky, with advanced training in Osteopathic, Regenerative, and Integrative Medicine, for patients in West Palm Beach and across South Florida with laboratory-confirmed iron deficiency.
Iron sucrose (Venofer) is an FDA-approved intravenous iron replacement product with over 70 years of clinical use and more than 25 million patient-years of worldwide clinical experience. It is one of the most extensively studied IV iron formulations available and has a well-characterized safety profile across multiple patient populations (Lopez et al., The Lancet, 2016).
Iron sucrose (Venofer®) is an FDA-approved prescription medication indicated for the treatment of iron deficiency anemia. At The Longevity Center FL, Venofer is administered only to patients with laboratory-confirmed iron deficiency, under physician supervision. This infusion requires pre-treatment laboratory evaluation and post-infusion monitoring. Iron sucrose is not appropriate for all patients, and it is not intended for use in patients with iron overload, hemochromatosis, or anemia not caused by iron deficiency. This service is not a substitute for evaluation by your primary care physician or hematologist. Potential risks include hypersensitivity reactions, hypotension, and other adverse effects; please review the full prescribing information with your physician.
Iron deficiency is among the most common nutritional deficiencies worldwide and a leading cause of anemia. A comprehensive review in the New England Journal of Medicine described iron deficiency anemia as a significant contributor to fatigue, impaired cognitive function, reduced exercise tolerance, and compromised immune response (Camaschella, NEJM, 2015). While oral iron supplementation is appropriate for many patients, intravenous administration may be clinically indicated when:
Research has demonstrated that IV iron sucrose may be associated with more rapid and reliable increases in hemoglobin and iron stores compared to oral supplementation in certain patient populations (Van Wyck et al., Kidney International, 2005).
Iron sucrose delivers iron directly into the bloodstream as an iron(III) hydroxide–sucrose complex. Following infusion, iron is rapidly taken up by the liver, spleen, and bone marrow, where the majority is utilized for red blood cell synthesis. Published pharmacokinetic data indicate that serum ferritin and transferrin saturation levels may begin to improve within 24 hours to one week following administration (Auerbach & Adamson, American Journal of Hematology, 2016).
Before any Venofer infusion, Dr. Kosubevsky requires laboratory confirmation of iron deficiency. This typically includes a complete blood count (CBC), serum ferritin, transferrin saturation (TSAT), and serum iron. These values establish that iron deficiency is present and that IV iron replacement is clinically appropriate. Patients with evidence of iron overload, hemochromatosis, or anemia unrelated to iron deficiency are not candidates for this therapy.
Venofer is administered as a slow intravenous infusion in our clinic, typically over 15 to 30 minutes per dose. The total cumulative dose and number of infusion sessions are determined by Dr. Kosubevsky based on your laboratory values and clinical presentation. Most patients receive their infusion comfortably in one of our IV chairs.
Patients are monitored for at least 30 minutes following each infusion to observe for any adverse reactions, including hypersensitivity or changes in blood pressure. Follow-up laboratory testing is performed after the treatment course is complete to evaluate response and determine whether additional infusions are needed.
For patients whose laboratory values confirm depleted iron stores and who have not responded adequately to oral supplementation or who cannot tolerate it.
Menstrual blood loss and the demands of pregnancy and postpartum recovery are among the most common causes of iron deficiency in women of reproductive age. IV iron may be appropriate when oral repletion is insufficient to keep pace with ongoing losses (Lopez et al., The Lancet, 2016).
For individuals with inflammatory bowel disease, celiac disease, gastric bypass history, or other gastrointestinal conditions that may impair oral iron absorption.
For patients preparing for elective surgery who have iron deficiency anemia and need to improve their hemoglobin levels before the procedure.
Iron deficiency—even without overt anemia—has been associated with reduced work capacity and exercise performance in peer-reviewed research (Haas & Brownlie, Journal of Nutrition, 2001). For active individuals with lab-confirmed deficiency, IV iron may support more efficient repletion than oral supplementation alone.
Dr. Benjamin Kosubevsky combines conventional medical training with advanced experience in integrative, regenerative, and osteopathic medicine. For patients receiving Venofer IV therapy, Dr. Kosubevsky provides:
Iron deficiency is one of the most correctable contributors to fatigue, reduced exercise tolerance, and impaired daily function. When oral supplementation is not enough, Venofer IV at The Longevity Center FL offers a proven, physician-supervised pathway to replenish iron stores efficiently and safely.
Schedule your consultation to determine whether Venofer IV is clinically appropriate for you.
The information on this page is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Iron sucrose (Venofer®) is an FDA-approved prescription medication and is administered at The Longevity Center FL only under physician supervision for patients with laboratory-confirmed iron deficiency. This therapy is not appropriate for all patients and is not indicated for anemia not caused by iron deficiency, iron overload, or hemochromatosis. Serious adverse reactions, including hypersensitivity and hypotension, have been reported with IV iron products; patients are monitored during and after infusion. Individual results vary based on each patient’s health history, laboratory findings, and clinical presentation. This service is not a substitute for evaluation and care by your primary care physician or hematologist. Always consult a qualified healthcare professional regarding any medical condition, symptom, medication, or treatment decision. Peer-reviewed research cited on this page reflects population-level findings and does not predict individual outcomes.
1. Camaschella C. Iron-Deficiency Anemia. New England Journal of Medicine. 2015;372(19):1832-1843.
2. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. The Lancet. 2016;387(10021):907-916.
3. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. American Journal of Hematology. 2016;91(1):31-38.
4. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis- dependent CKD. Kidney International. 2005;68(6):2846-2856.
5. Haas JD, Brownlie T IV. Iron Deficiency and Reduced Work Capacity: A Critical Review of the Research to Determine a Causal Relationship. Journal of Nutrition. 2001;131(2):676S-690S.
Schedule your appointment today and take the first step toward a healthier, more balanced life.
Schedule an Appointment